Federal regulators are attempting to streamline the development of lower-cost alternatives to biologic medicines that many Americans rely on for autoimmune diseases and cancer care. In a move aimed at reducing patient out-of-pocket expenses and expanding access, the Food and Drug Administration released guidance intended to simplify the evidence required for biosimilar development and to trim unnecessary testing.
Biologic drugs are produced from living cells rather than by chemical synthesis, and have driven major advances in treating immune disorders, eye diseases, and certain cancers since the late 1990s. However, their high prices have remained a persistent barrier to access.
For years, biotech manufacturers argued that copying complex biologics would be infeasible. That view shifted with the 2010 health reform under President Obama, which instructed the FDA to establish a pathway for approving biosimilars—drugs designed to be highly similar to an approved biologic.
The FDA’s current pathway, finalized in 2015, requires studies that show patients respond similarly to biosimilars when compared with the original biologic. The agency’s latest proposal seeks to ease that standard, describing it as an “unnecessary resource-intensive requirement.” Health Secretary Robert F. Kennedy Jr. framed the proposal as a way to promote competition, lower prices, and accelerate access to lifesaving medicines.
The draft guidance represents the first step in a lengthy regulatory process. It offers a tentative set of recommendations for drugmakers rather than binding rules. The FDA will accept publiccomments on the proposal for 60 days. Following the comment period, the agency will review and revise the document. The final guidance is expected within three to six months but will remain non-binding; it will function as recommendations for biosimilar developers.
Biosimilar competition has already yielded price relief for patients using biologics such as Humira. Nevertheless, immediate price reductions are not guaranteed and will depend on factors including insurance coverage and whether a biosimilar is included on a pharmacy benefit manager’s formulary.
Industry experts say that, over time, biosimilar competition can incentivize price reductions for biologics and lead to larger rebates that keep products on formularies. The evolving landscape may ultimately produce meaningful cost savings for patients, even as health plans and providers navigate formulary decisions and coverage terms.
Related topics:
